ClinicalTrials.gg
WithdrawnNCT03710941Updated Apr 29, 2019

Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis

A Phase 2 interventional study of REGN2477+REGN1033 and Matching placebo in Sporadic Inclusion Body Myositis, sponsored by Regeneron Pharmaceuticals. Withdrawn. Open to participants aged 45 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-04-29.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Why this study was withdrawn
The study was withdrawn due to an internal decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
45 Years to 75 Years
Sex
All
01

Study summary

The primary objective of the study is to evaluate the efficacy of REGN2477+REGN1033 in combination on total lean mass, as measured by Dual-energy X-ray absorptiometry (DXA) in patients with sporadic inclusion body myositis (sIBM).

The secondary objectives of the study are:

  • To evaluate the efficacy of REGN2477+REGN1033 on the IBM-Functional Rating Scale (IBM-FRS)
  • To evaluate the efficacy of REGN2477+REGN1033 on the sIBM Physical Functioning Assessment (sIFA)
  • To evaluate the safety and tolerability of REGN2477+REGN1033
  • To evaluate the effects of REGN2477+REGN1033 on body composition by DXA, including appendicular lean mass and total fat mass
  • To evaluate the efficacy of REGN2477+REGN1033 on measures of muscle performance and physical function
  • To evaluate the efficacy of REGN2477+REGN1033 on patient reported outcome measures including the fear of falling, falls and near falls, and health-related quality of life
  • To evaluate the pharmacokinetic(s) (PK) profile of REGN2477+REGN1033, including functional REGN2477 and functional REGN1033 concentrations in serum over time
  • To evaluate the immunogenicity of REGN2477+REGN1033
02

Conditions studied

  • Sporadic Inclusion Body Myositis
03

In context

Myositis, Inclusion Body

65 studies on the registry are indexed under Myositis, Inclusion Body; 10 are open to participants now.

Browse Myositis, Inclusion Body studies →

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Men and * women
  • Diagnosed with sIBM based on the European Neuromuscular Centre (ENMC) IBM Research Diagnostic Criteria
  • Ability to walk ≥150 meters, with or without a walking aid such as cane or walker, in 6 minutes.
  • Ability to climb 4 steps of stairs unassisted (may use handrails)
  • Willing and able to comply with clinic visits and study-related procedures

Key Exclusion Criteria:

  • Other neurological conditions (eg, hemiplegia post stroke, Parkinson's) or musculo-skeletal conditions (eg, severe osteoarthritis) causing mobility impairment
  • (MMSE) score \<24
  • Ongoing, chronic, high-dose (>20 mg prednisone equivalent per day), systemic therapy within 6 weeks prior to screening.
  • Any condition that precludes adequate intake of energy and protein; malnutrition; presence of an eating disorder.
  • Unintentional weight loss of ≥10% in the past 6 months (patient-reported)
  • Hospitalization for heart failure in last year or Class 4
  • History of hypertrophic cardiomyopathy
  • Any drugs known to influence muscle mass and performance such as anabolic steroids or growth hormone within 6 weeks prior to screening
  • Unable to fit on the site's DXA scanner table, within borders for scanning of total lean mass

Note: Other protocol Inclusion/Exclusion criteria apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    REGN2477+REGN1033

    Single, sequential, repeat-dose IV or matching placebo

    Drug: REGN2477+REGN1033

  • Experimental
    Placebo

    Single, sequential, repeat-dose IV

    Drug: Matching placebo

Interventions

  • DrugREGN2477+REGN1033

    Drug pages: Garetosmab · Trevogrumab

    Single, sequential, repeat-dose Intravenous (IV) or matching placebo

  • DrugMatching placebo

    Single, sequential, repeat-dose Intravenous (IV)

06

What researchers measure

Primary outcomes

  1. Percent change in total lean mass as measured by dual-energy X-ray absorptiometry (DXA)

    Time frame: Up to Week 20

Secondary outcomes

  1. Change in the Inclusion Body Myositis-Functional Rating Scale (IBM-FRS)

    Time frame: Up to Week 26

  2. Change in the Sporadic inclusion body myositis (sIBM) Physical Functioning Assessment (sIFA)

    Time frame: Up to Week 26

  3. Incidence and severity of treatment-emergent adverse events (TEAEs)

    Time frame: Up to Week 30

  4. Percent change in total and regional body composition (including lean mass and fat mass) as measured by DXA

    Time frame: Up to Week 30

  5. Absolute change in total and regional body composition (including lean mass and fat mass) as measured by DXA

    Time frame: Up to Week 30

  6. Change in the 1-repetition maximum (1-RM) chest press strength

    Time frame: Up to Week 26

  7. Change in hand-grip strength as measured by dynamometry

    Time frame: Up to Week 26

  8. Change in distance walked in the 6-minute walk test (6MWT)

    Time frame: Up to Week 26

  9. Change in time to complete the 10-meter walk test (10MWT)

    Time frame: Up to Week 26

  10. Change in instrumented stair climb power

    Time frame: Up to Week 26

  11. Change in instrumented, sensor-based sit-to-stand test time

    Time frame: Up to Week 26

  12. Change in fear of falling as measured via the Falls Efficacy Scale-International (FES-I)

    Time frame: Up to Week 30

  13. Change in Patient Global Impression of Severity assessments (PGIS/PGIC)

    Time frame: Up to Week 30

  14. Change in Patient Global Impression of Change Items assessments (PGIS/PGIC)

    Time frame: Up to Week 30

  15. Change in Clinician Global Impression of Severity assessments (CGIS/CGIC)

    Time frame: Up to Week 30

  16. Change in Clinician Global Impression of Change Items assessments (CGIS/CGIC)

    Time frame: Up to Week 30

  17. Change in 36-item Short Form Health Survey (SF-36), including the Physical Function Items (PF-10) and the Vitality Scale of the SF-36

    Time frame: Up to Week 30

  18. Change in Thigh muscle volume as measured by MRI (sub-study)

    Time frame: Up to Week 30

  19. Frequency of falls and near-falls as measured by the Hopkins Falls Grading Scale

    Time frame: Up to Week 30

  20. Pharmacokinetics (PK) profile of REGN2477

    Assessed via serum concentration of REGN2477 over time

    Time frame: Up to Week 30

  21. Pharmacokinetics (PK) profile of REGN1033

    Assessed via serum concentration of REGN1033 over time

    Time frame: Up to Week 30

  22. Immunogenicity of REGN2477+REGN1033

    As determined by the presence or absence of anti-drug antibodies (ADA)

    Time frame: Up to Week 30

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2019; primary completion for Aug 2020, 18 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2018
First posted
Oct 18, 2018
StartEst.
Feb 19, 2019
Primary completionEst.
Aug 27, 2020
CompletionEst.
Nov 5, 2020
Last update
Apr 29, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03710941
Responsible party
Sponsor
First posted
Oct 18, 2018
Start date
Feb 19, 2019 (estimated)
Primary completion
Aug 27, 2020 (estimated)
Completion
Nov 5, 2020 (estimated)
Last update
Apr 29, 2019

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Garetosmab · Trevogrumab

Start the discussion